

Gianfranco Ferraccioli

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5690495/gianfranco-ferraccioli-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

269
papers

17,538
citations

58
h-index

128
g-index

305
ext. papers

20,868
ext. citations

4.9
avg, IF

5.93
L-index

#	Paper	IF	Citations
269	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2569-81		4825
268	2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1580-8	2.4	2158
267	EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCSIT). <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 34-45	2.4	508
266	Efficacy and safety of rituximab in type II mixed cryoglobulinemia. <i>Blood</i> , 2003 , 101, 3827-34	2.2	392
265	Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 909-20	2.4	308
264	Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. <i>Arthritis Research and Therapy</i> , 2008 , 10, R30	5.7	308
263	Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. <i>Arthritis and Rheumatism</i> , 2007 , 56, 3896-908		270
262	2016 update of the EULAR recommendations for the management of early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 948-959	2.4	243
261	Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2029-33		219
260	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2582-91		182
259	Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study. <i>Arthritis Research and Therapy</i> , 2010 , 12, R42	5.7	160
258	Hepatitis C virus within a malignant lymphoma lesion in the course of type II mixed cryoglobulinemia. <i>Blood</i> , 1995 , 86, 1887-1892	2.2	152
257	Consensus statement on the use of rituximab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 143-50	2.4	142
256	Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. <i>Rheumatology</i> , 2006 , 45, 842-6	3.9	140
255	Obesity and reduction of the response rate to anti-tumor necrosis factor β in rheumatoid arthritis: an approach to a personalized medicine. <i>Arthritis Care and Research</i> , 2013 , 65, 94-100	4.7	137
254	Clinical and ultrasonographic remission determines different chances of relapse in early and long standing rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 172-5	2.4	135
253	Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. <i>Arthritis and Rheumatism</i> , 2008 , 58, 2642-51		135

252	The role of biosimilars in the treatment of rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 322-8	2.4	134
251	Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. <i>Annals of Internal Medicine</i> , 2004 , 141, 493-500	8	134
250	B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. <i>Arthritis Research and Therapy</i> , 2010 , 12, R54	5.7	127
249	Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: clinical and molecular findings do not support a bone marrow pathologic diagnosis of indolent B cell lymphoma. <i>Arthritis and Rheumatism</i> , 2000 , 43, 94-102		126
248	Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. <i>Autoimmunity Reviews</i> , 2012 , 12, 225-9	13.6	125
247	A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006 , 1, 925-32	6.9	119
246	Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis. <i>Nature Medicine</i> , 2020 , 26, 1295-1306	50.5	115
245	Brief report: successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: an Italian multicenter study. <i>Arthritis and Rheumatism</i> , 2012 , 64, 1970-7		112
244	MicroRNA-155-at the Critical Interface of Innate and Adaptive Immunity in Arthritis. <i>Frontiers in Immunology</i> , 2017 , 8, 1932	8.4	105
243	Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2015 , 44, 428-36	5.3	102
242	TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma. <i>Autoimmunity Reviews</i> , 2005 , 4, 153-61	13.6	99
241	Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. <i>British Journal of Rheumatology</i> , 2002 , 41, 1346-56		99
240	Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. <i>Rheumatology</i> , 2015 , 54, 891-8	3.9	93
239	Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. <i>Arthritis and Rheumatism</i> , 2010 , 62, 674-82		92
238	Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study. <i>Arthritis and Rheumatology</i> , 2016 , 68, 2527-39	9.5	92
237	Recognizing and treating myocarditis in recent-onset systemic sclerosis heart disease: potential utility of immunosuppressive therapy in cardiac damage progression. <i>Seminars in Arthritis and Rheumatism</i> , 2014 , 43, 526-35	5.3	91
236	Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 858-62	2.4	91
235	Characterization of prelymphomatous stages of B cell lymphoproliferation in Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 1997 , 40, 318-31		91

234	Salivary gland B cell lymphoproliferative disorders in Sjögren's syndrome present a restricted use of antigen receptor gene segments similar to those used by hepatitis C virus-associated non-Hodgkins's lymphomas. <i>European Journal of Immunology</i> , 2002 , 32, 903-10	6.1	90
233	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 482-92	2.4	87
232	Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008 , 35, 1256-64	4.1	87
231	B-Lymphocyte stimulator (BLyS) up-regulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection. <i>Rheumatology</i> , 2007 , 46, 37-43	3.9	85
230	Body weight, gender and response to TNF- β blockers in axial spondyloarthritis. <i>Rheumatology</i> , 2014 , 53, 875-81	3.9	83
229	Obesity as a risk and severity factor in rheumatic diseases (autoimmune chronic inflammatory diseases). <i>Frontiers in Immunology</i> , 2014 , 5, 576	8.4	82
228	Gastric mucosa as an additional extrahepatic localization of hepatitis C virus: viral detection in gastric low-grade lymphoma associated with autoimmune disease and in chronic gastritis. <i>Hepatology</i> , 2000 , 31, 182-9	11.2	77
227	Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. <i>Arthritis and Rheumatism</i> , 2008 , 59, 32-41		76
226	Interleukin-1 β and interleukin-6 in arthritis animal models: roles in the early phase of transition from acute to chronic inflammation and relevance for human rheumatoid arthritis. <i>Molecular Medicine</i> , 2010 , 16, 552-7	6.2	75
225	Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. <i>Journal of Rheumatology</i> , 2008 , 35, 1944-9	4.1	75
224	MicroRNA-155 influences B-cell function through PU.1 in rheumatoid arthritis. <i>Nature Communications</i> , 2016 , 7, 12970	17.4	72
223	Usefulness of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography in patients with large-vessel vasculitis: a systematic review. <i>Clinical Rheumatology</i> , 2011 , 30, 1265-75	3.9	72
222	Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. <i>Rheumatology</i> , 2012 , 51, 157-68	3.9	72
221	Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. <i>Arthritis and Rheumatism</i> , 1996 , 39, 1006-15		72
220	The metabolic syndrome: the crossroads between rheumatoid arthritis and cardiovascular risk. <i>Autoimmunity Reviews</i> , 2011 , 10, 582-9	13.6	71
219	Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. <i>Annals of the Rheumatic Diseases</i> , 2002 , 61, 358-61	2.4	69
218	Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , 2017 , 8, 369	5.6	68
217	Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 583-9	2.4	68

216	The need for personalised medicine for rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 4-7	2.4	67
215	TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2008 , 27, 833-9	3.9	67
214	IL-1B and IL-1RN gene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy. <i>Pharmacogenomics</i> , 2006 , 7, 683-95	2.6	62
213	EULAR definition of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 31-35	2.4	61
212	Skin ulcers in systemic sclerosis: determinants of presence and predictive factors of healing. <i>Journal of the American Academy of Dermatology</i> , 2009 , 60, 426-35	4.5	60
211	B cells in systemic sclerosis: a possible target for therapy. <i>Autoimmunity Reviews</i> , 2011 , 10, 624-30	13.6	57
210	Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-progression. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1292-5	2.4	56
209	Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study. <i>Rheumatology</i> , 2015 , 54, 792-7	3.9	55
208	Validation of the classification criteria for cryoglobulinaemic vasculitis. <i>Rheumatology</i> , 2014 , 53, 2209-13	3.9	55
207	Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. <i>Clinical Rheumatology</i> , 2016 , 35, 1683-9	3.9	52
206	MicroRNA-34a dependent regulation of AXL controls the activation of dendritic cells in inflammatory arthritis. <i>Nature Communications</i> , 2017 , 8, 15877	17.4	51
205	Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis. <i>Respiratory Research</i> , 2005 , 6, 96	7.3	51
204	Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, 449-56	2.2	51
203	Peripheral neuropathy in essential mixed cryoglobulinaemia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1992 , 55, 116-20	5.5	48
202	Rituximab for the treatment of type II mixed cryoglobulinemia. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2252-4; author reply 2254-5		47
201	Tapering and discontinuation of TNF-blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission. <i>Arthritis Research and Therapy</i> , 2016 , 18, 39	5.7	46
200	Clinical heterogeneity of SAPHO syndrome: challenging diagnose and treatment. <i>Clinical Rheumatology</i> , 2017 , 36, 2151-2158	3.9	46
199	The human salivary proteome: a critical overview of the results obtained by different proteomic platforms. <i>Expert Review of Proteomics</i> , 2012 , 9, 33-46	4.2	46

198	Mild sialoadenitis: a common finding in patients with hepatitis C virus infection. <i>Scandinavian Journal of Gastroenterology</i> , 1994 , 29, 940-2	2.4	46
197	Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2002 , 29, 1847-50	4.1	46
196	Synovial fluid-derived T helper 17 cells correlate with inflammatory activity in arthritis, irrespectively of diagnosis. <i>Clinical Immunology</i> , 2011 , 138, 107-16	9	45
195	Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 80, 275-81	6.1	45
194	Endothelial progenitors in pulmonary hypertension: new pathophysiology and therapeutic implications. <i>European Respiratory Journal</i> , 2010 , 35, 418-25	13.6	44
193	Development of a five-year mortality model in systemic sclerosis patients by different analytical approaches. <i>Clinical and Experimental Rheumatology</i> , 2010 , 28, S18-27	2.2	44
192	Porphyromonas gingivalis and the pathogenesis of rheumatoid arthritis: analysis of various compartments including the synovial tissue. <i>Arthritis Research and Therapy</i> , 2013 , 15, R66	5.7	43
191	Tumor necrosis factor-alpha gene polymorphism in severe and mild-moderate rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2002 , 29, 29-33	4.1	41
190	The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the Quest-RA program. <i>Clinical and Experimental Rheumatology</i> , 2014 , 32, 869-77	2.2	39
189	PTPN22 1858C>T polymorphism distribution in Europe and association with rheumatoid arthritis: case-control study and meta-analysis. <i>PLoS ONE</i> , 2011 , 6, e24292	3.7	38
188	Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1228-1236	2.4	37
187	Extrasalivary lymphoma development in Sjögren's syndrome: clonal evolution from parotid gland lymphoproliferation and role of local triggering. <i>Arthritis and Rheumatism</i> , 2003 , 48, 3181-6		37
186	Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 249-52	2.4	36
185	Widespread clonal B-cell disorder in Sjögren's syndrome predisposing to Helicobacter pylori-related gastric lymphoma. <i>Gastroenterology</i> , 1996 , 110, 1969-74	13.3	36
184	True primary Sjögren's syndrome in a subset of patients with hepatitis C infection: a model linking chronic infection to chronic sialadenitis. <i>Israel Medical Association Journal</i> , 2002 , 4, 1101-5	0.9	36
183	Refractory adult-onset Still disease complicated by macrophage activation syndrome and acute myocarditis: A case report treated with high doses (8 mg/kg/d) of anakinra. <i>Medicine (United States)</i> , 2017 , 96, e6656	1.8	35
182	Patient-reported impact of spondyloarthritis on work disability and working life: the ATLANTIS survey. <i>Arthritis Research and Therapy</i> , 2016 , 18, 78	5.7	35
181	Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung disease. <i>Clinical Respiratory Journal</i> , 2012 , 6, 9-17	1.7	33

180	Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. <i>Arthritis Care and Research</i> , 2011 , 63, 711-20	4.7	33
179	The -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 584-90	2.4	32
178	Colour Doppler ultrasonography evaluation of vascularization in the wrist and finger joints in rheumatoid arthritis patients and healthy subjects. <i>European Journal of Radiology</i> , 2012 , 81, 1834-8	4.7	31
177	Preliminary classification of nonmalignant B cell proliferation in Sjögren's syndrome: perspectives on pathobiology and treatment based on an integrated clinico-pathologic and molecular study approach. <i>Blood Cells, Molecules, and Diseases</i> , 2001 , 27, 757-66	2.1	31
176	Prognostic Role of Ventricular Ectopic Beats in Systemic Sclerosis: A Prospective Cohort Study Shows ECG Indexes Predicting the Worse Outcome. <i>PLoS ONE</i> , 2016 , 11, e0153012	3.7	31
175	The potential role of Th17 in mediating the transition from acute to chronic autoimmune inflammation: rheumatoid arthritis as a model. <i>Discovery Medicine</i> , 2011 , 11, 413-24	2.5	31
174	-238 and +489 TNF-alpha along with TNF-RII gene polymorphisms associate with the diffuse phenotype in patients with Systemic Sclerosis. <i>Immunology Letters</i> , 2005 , 96, 103-8	4.1	30
173	Cyclosporine-A plus steroids versus steroids alone in the 12-month treatment of systemic lupus erythematosus. <i>International Journal of Clinical and Laboratory Research</i> , 2000 , 30, 67-73		30
172	Computer-aided quantification of interstitial lung disease from high resolution computed tomography images in systemic sclerosis: correlation with visual reader-based score and physiologic tests. <i>BioMed Research International</i> , 2015 , 2015, 834262	3	29
171	Cardiac troponin T and NT-proBNP as diagnostic and prognostic biomarkers of primary cardiac involvement and disease severity in systemic sclerosis: A prospective study. <i>European Journal of Internal Medicine</i> , 2019 , 60, 46-53	3.9	29
170	Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis. <i>PLoS ONE</i> , 2012 , 7, e40362	3.7	28
169	Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 963-9	2.4	27
168	Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA. <i>Clinical Rheumatology</i> , 2018 , 37, 315-321	3.9	27
167	JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy. <i>Journal of Leukocyte Biology</i> , 2019 , 106, 1063-1068	6.5	27
166	Thrombogenicity of TNF alpha in rheumatoid arthritis defined through biological probes: TNF alpha blockers. <i>Autoimmunity Reviews</i> , 2004 , 3, 261-6	13.6	27
165	Toll-like receptor 4 mediates endothelial cell activation through NF-B but is not associated with endothelial dysfunction in patients with rheumatoid arthritis. <i>PLoS ONE</i> , 2014 , 9, e99053	3.7	27
164	Collagen Specific T-Cell Repertoire and HLA-DR Alleles: Biomarkers of Active Refractory Rheumatoid Arthritis. <i>EBioMedicine</i> , 2015 , 2, 2037-45	8.8	26
163	Modeling the ternary complex TCR-Vbeta/CollagenII(261-273)/HLA-DR4 associated with rheumatoid arthritis. <i>PLoS ONE</i> , 2010 , 5, e11550	3.7	26

162	When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS). <i>RMD Open</i> , 2016 , 2, e000221	5.9	26
161	Leflunomide treatment in elderly patients with rheumatoid or psoriatic arthritis: retrospective analysis of safety and adherence to treatment. <i>Drugs and Aging</i> , 2009 , 26, 395-402	4.7	25
160	Interstitial granulomatous dermatitis in rheumatoid arthritis responsive to etanercept. <i>Clinical Rheumatology</i> , 2010 , 29, 99-101	3.9	25
159	Efficacy of cyclosporin-A in the long-term management of thrombocytopenia associated with systemic lupus erythematosus. <i>Lupus</i> , 2006 , 15, 76-9	2.6	25
158	<i>Helicobacter pylori</i> associated antigastric autoantibodies: role in Sjögren's syndrome gastritis. <i>Helicobacter</i> , 2004 , 9, 46-53	4.9	25
157	Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinaemic vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2012 , 30, S48-52	2.2	25
156	Characterization of inflammatory cell infiltrate of scleroderma skin: B cells and skin score progression. <i>Arthritis Research and Therapy</i> , 2018 , 20, 75	5.7	24
155	An autosomal recessive DNASE1L3-related autoimmune disease with unusual clinical presentation mimicking systemic lupus erythematosus. <i>Lupus</i> , 2017 , 26, 768-772	2.6	24
154	Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced Osteoporosis TOol (GIOTTO) study. <i>Reumatismo</i> , 2017 , 69, 30-39	1.1	24
153	B-cell subsets in the joint compartments of seropositive and seronegative rheumatoid arthritis (RA) and No-RA arthritides express memory markers and ZAP70 and characterize the aggregate pattern irrespectively of the autoantibody status. <i>Molecular Medicine</i> , 2011 , 17, 901-9	6.2	24
152	The polymerase chain reaction detects B cell clonalities in patients with Sjögren's syndrome and suspected malignant lymphoma. <i>Journal of Rheumatology</i> , 1994 , 21, 1497-501	4.1	24
151	Infections, B cell receptor activation and autoimmunity: different check-point impairments lead to autoimmunity, clonal B cell expansion and fibrosis in different immunological settings. <i>Autoimmunity Reviews</i> , 2007 , 7, 109-13	13.6	23
150	Local cytokine expression in the progression toward B cell malignancy in Sjögren's syndrome. <i>Journal of Rheumatology</i> , 1995 , 22, 1674-80	4.1	23
149	Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 453-459	2.4	22
148	ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature. <i>Arthritis Research and Therapy</i> , 2009 , 11, R163	5.7	22
147	Proteomic approaches to Sjögren's syndrome: a clue to interpret the pathophysiology and organ involvement of the disease. <i>Autoimmunity Reviews</i> , 2010 , 9, 622-6	13.6	22
146	Renal interstitial cells, proteinuria and progression of lupus nephritis: new frontiers for old factors. <i>Lupus</i> , 2008 , 17, 533-40	2.6	22
145	Polymorphism of immunoglobulin enhancer element HS1,2A: allele *2 associates with systemic sclerosis. Comparison with HLA-DR and DQ allele frequency. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 1210-5	2.4	22

144	Osteoporosis and bone metabolism in postmenopausal women with osteoarthritis of the hand. <i>Menopause</i> , 2006 , 13, 462-6	2.5	22
143	Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016 , 18, 294	5.7	22
142	Driving chronicity in rheumatoid arthritis: perpetuating role of myeloid cells. <i>Clinical and Experimental Immunology</i> , 2018 , 193, 13-23	6.2	21
141	Temporal ultrasonography findings in temporal arteritis: early disappearance of halo sign after only 2 days of steroid treatment. <i>Rheumatology</i> , 2013 , 52, 622	3.9	21
140	Controlled multicenter trial of tiopronin and d-penicillamine for rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1982 , 25, 923-9		21
139	Position paper of Italian rheumatologists on the use of biosimilar drugs. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, 1-4	2.2	21
138	Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2017 , 36, 2655-2665	3.9	20
137	Somatomedin C (insulin-like growth factor 1) levels decrease during acute changes of stress related hormones. Relevance for fibromyalgia. <i>Journal of Rheumatology</i> , 1994 , 21, 1332-4	4.1	20
136	Prevalence and Determinants of Peripheral Microvascular Endothelial Dysfunction in Rheumatoid Arthritis Patients: A Multicenter Cross-Sectional Study. <i>Mediators of Inflammation</i> , 2018 , 2018, 6548715	4.3	19
135	Chemerin and PEDF Are Metaflammation-Related Biomarkers of Disease Activity and Obesity in Rheumatoid Arthritis. <i>Frontiers in Medicine</i> , 2018 , 5, 207	4.9	19
134	Memory B cell subsets and plasmablasts are lower in early than in long-standing rheumatoid arthritis. <i>BMC Immunology</i> , 2014 , 15, 28	3.7	19
133	GISEA: an Italian biological agents registry in rheumatology. <i>Reumatismo</i> , 2011 , 63, 155-64	1.1	19
132	Polymorphisms of the IgH enhancer HS1.2 and risk of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1309-15	2.4	19
131	Quality indicators in rheumatoid arthritis: results from the METEOR database. <i>Rheumatology</i> , 2015 , 54, 1630-9	3.9	18
130	Rheumatoid arthritis and Alzheimer's disease: genetic and epigenetic links in inflammatory regulation. <i>Discovery Medicine</i> , 2012 , 14, 379-88	2.5	18
129	Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. <i>Frontiers in Pharmacology</i> , 2019 , 10, 296	5.6	17
128	Synovial Predictors of Differentiation to Definite Arthritis in Patients With Seronegative Undifferentiated Peripheral Inflammatory Arthritis: microRNA Signature, Histological, and Ultrasound Features. <i>Frontiers in Medicine</i> , 2018 , 5, 186	4.9	17
127	Cilostazol improves the response to ischemia in diabetic mice by a mechanism dependent on PPAR α . <i>Molecular and Cellular Endocrinology</i> , 2013 , 381, 80-7	4.4	17

126	Life-threatening arrhythmias in a scleroderma patient: the role of myocardial inflammation in arrhythmic outburst. <i>Scandinavian Journal of Rheumatology</i> , 2017 , 46, 78-80	1.9	17
125	ETThymosins and interstitial lung disease: study of a scleroderma cohort with a one-year follow-up. <i>Respiratory Research</i> , 2011 , 12, 22	7.3	17
124	Hepatocyte growth factor and transforming growth factor beta1 ratio at baseline can predict early response to cyclophosphamide in systemic lupus erythematosus nephritis. <i>Arthritis and Rheumatism</i> , 2006 , 54, 3633-9		17
123	Lack of Hcv Infection in Malignant, Cells Refutes the Hypothesis of a Direct Transforming Action of the Virus in the Pathogenesis of Hcv-Associated B-Cell Nhls. <i>Tumori</i> , 2002 , 88, 400-406	1.7	17
122	Haematopoietic stem cell transplantation (HSCT) in a patient with Sjögren's syndrome and lung malt lymphoma cured lymphoma not the autoimmune disease. <i>Annals of the Rheumatic Diseases</i> , 2001 , 60, 174-6	2.4	17
121	Adiposity, joint and systemic inflammation: the additional risk of having a metabolic syndrome in rheumatoid arthritis. <i>Swiss Medical Weekly</i> , 2011 , 141, w13211	3.1	17
120	B cell activating factor (BAFF) and BAFF receptors: fakes and facts. <i>Clinical and Experimental Immunology</i> , 2017 , 190, 291-292	6.2	16
119	Increase of bone mineral density and anabolic variables in patients with rheumatoid arthritis resistant to methotrexate after cyclosporin A therapy. <i>Journal of Rheumatology</i> , 1996 , 23, 1539-42	4.1	16
118	QTc interval prolongation in Systemic Sclerosis: Correlations with clinical variables and arrhythmic risk. <i>International Journal of Cardiology</i> , 2017 , 239, 33	3.2	15
117	Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register. <i>Joint Bone Spine</i> , 2014 , 81, 508-12	2.9	15
116	To switch or not to switch after a poor response to a TNF blocker? It is not only a matter of ACR20 OR ACR50. <i>Autoimmunity Reviews</i> , 2012 , 11, 558-62	13.6	15
115	Citrullination: the loss of tolerance and development of autoimmunity in rheumatoid arthritis. <i>Reumatismo</i> , 2008 , 60, 85-94	1.1	15
114	Diagnostic performance of anti-citrullinated peptide antibodies for the diagnosis of rheumatoid arthritis: the relevance of likelihood ratios. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010 , 48, 829-34	5.9	15
113	Improved endothelial function after endothelin receptor blockade in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2009 , 60, 1840-4		15
112	MR imaging of atlantoaxial joint in early rheumatoid arthritis. <i>Radiologia Medica</i> , 2010 , 115, 1111-20	6.5	15
111	Anti-Müllerian hormone serum levels in systemic lupus erythematosus patients: Influence of the disease severity and therapy on the ovarian reserve. <i>Endocrine</i> , 2019 , 63, 369-375	4	15
110	Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability. <i>Clinical Rheumatology</i> , 2016 , 35, 2649-2656	3.9	14
109	Is ACPA positivity the main driver for rheumatoid arthritis treatment? Pros and cons. <i>Autoimmunity Reviews</i> , 2017 , 16, 1096-1102	13.6	14

108	Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs. <i>Rheumatology</i> , 2012 , 51 Suppl 5, v12-21	3.9	14
107	Function and dysfunction of dendritic cells in autoimmune rheumatic diseases. <i>Human Immunology</i> , 2009 , 70, 360-73	2.3	14
106	Mycophenolate mofetil and intravenous dexamethasone in the treatment of persistent lupus myelitis. <i>Journal of Rheumatology</i> , 2007 , 34, 588-91	4.1	14
105	Pathogenetic, clinical and pharmaco-economic assessment in rheumatoid arthritis (RA). <i>Internal and Emergency Medicine</i> , 2011 , 6 Suppl 1, 11-5	3.7	13
104	Proteome analysis of biological fluids from autoimmune-rheumatological disorders. <i>Proteomics - Clinical Applications</i> , 2011 , 5, 78-89	3.1	13
103	The Relevance of VDJ PCR Protocols in Detecting B-Cell Clonal Expansion in Lymphomas and Other Lymphoproliferative Disorders. <i>Tumori</i> , 1995 , 81, 405-409	1.7	13
102	Differential synovial tissue biomarkers among psoriatic arthritis and rheumatoid factor/anti-citrulline antibody-negative rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2019 , 21, 116	5.7	12
101	The role of high-mobility group box protein 1 in collagen antibody-induced arthritis is dependent on vascular endothelial growth factor. <i>Clinical and Experimental Immunology</i> , 2016 , 184, 62-72	6.2	12
100	Detection of bone erosions in early rheumatoid arthritis: 3D ultrasonography versus computed tomography. <i>Clinical Rheumatology</i> , 2015 , 34, 1181-6	3.9	12
99	Evidence-based algorithm for diagnosis and assessment in psoriatic arthritis: results by Italian DELphi in psoriatic Arthritis (IDEA). <i>Reumatismo</i> , 2016 , 68, 126-136	1.1	12
98	Tumour-associated antigens in systemic sclerosis patients with interstitial lung disease: association with lung involvement and cancer risk. <i>Rheumatology</i> , 2015 , 54, 1991-9	3.9	11
97	Free light chains of immunoglobulins in patients with systemic sclerosis: correlations with lung involvement and inflammatory milieu. <i>Journal of Clinical Pathology</i> , 2018 , 71, 620-625	3.9	11
96	Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs. <i>Joint Bone Spine</i> , 2018 , 85, 455-459	2.9	11
95	Synovial B cells of rheumatoid arthritis express ZAP-70 which increases the survival and correlates with the inflammatory and autoimmune phenotype. <i>Clinical Immunology</i> , 2009 , 131, 98-108	9	11
94	The prognostic significance of the Birmingham Vasculitis Activity Score (BVAS) with systemic vasculitis patients transferred to the intensive care unit (ICU). <i>Medicine (United States)</i> , 2016 , 95, e5506	1.8	11
93	Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis. <i>RMD Open</i> , 2018 , 4, e000667	5.9	11
92	Checkpoint inhibitors (CPI) and autoimmune chronic inflammatory diseases (ACIDs): tolerance and loss of tolerance in the occurrence of immuno-rheumatologic manifestations. <i>Clinical Immunology</i> , 2020 , 214, 108395	9	9
91	The UltraSound-CLinical ARthritis Activity (US-CLARA) index: Properties of a new composite disease activity index for rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2018 , 47, 619-629	5.3	9

90	Biomolecular features of inflammation in obese rheumatoid arthritis patients: management considerations. <i>Expert Review of Clinical Immunology</i> , 2016 , 12, 751-62	5.1	9
89	The Role of High-Mobility Group Box-1 and Its Crosstalk with Microbiome in Rheumatoid Arthritis. <i>Mediators of Inflammation</i> , 2017 , 2017, 5230374	4.3	9
88	Environmental Pollution by Benzene and PM and Clinical Manifestations of Systemic Sclerosis: A Correlation Study. <i>International Journal of Environmental Research and Public Health</i> , 2017 , 14,	4.6	9
87	A vascular endothelial growth factor deficiency characterises scleroderma lung disease. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1461-5	2.4	9
86	Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37, 649-655	2.2	9
85	Basic immunology may lead to translational therapeutic rationale: SARS-CoV-2 and rheumatic diseases. <i>European Journal of Clinical Investigation</i> , 2020 , 50, e13342	4.6	8
84	Abatacept in the treatment of psoriatic arthritis: biological and clinical profiles of the responders. <i>Immunotherapy</i> , 2018 , 10, 807-821	3.8	8
83	Overweight/obesity affects histological features and inflammatory gene signature of synovial membrane of Rheumatoid Arthritis. <i>Scientific Reports</i> , 2019 , 9, 10420	4.9	8
82	Baseline Shoulder Ultrasonography Is Not a Predictive Marker of Response to Glucocorticoids in Patients with Polymyalgia Rheumatica: A 12-month Followup Study. <i>Journal of Rheumatology</i> , 2017 , 44, 241-247	4.1	7
81	The B side of rheumatoid arthritis pathogenesis. <i>Pharmacological Research</i> , 2019 , 149, 104465	10.2	7
80	Body mass index as a driver of selection of biologic therapy in rheumatoid arthritis. Results from the US-CLARA study. <i>European Journal of Internal Medicine</i> , 2019 , 66, 57-61	3.9	7
79	Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register). <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, e31	2.4	7
78	Absence of human parvovirus B19 DNA in myoepithelial sialadenitis of primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2002 , 61, 855-6	2.4	7
77	Adherence to Treat-to-target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort. <i>Journal of Rheumatology</i> , 2020 , 47, 809-819	4.1	7
76	The pathogenesis of microthrombi in COVID-19 cannot be controlled by DOAC: NETosis should be the target. <i>Journal of Internal Medicine</i> , 2021 , 289, 420-421	10.8	7
75	Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 1018-1028	2.2	7
74	Interleukin-6 and IgA-rheumatoid factor are crucial for baseline erosiveness, and anti-citrullinated peptide antibodies for radiographic progression in early rheumatoid arthritis treated according to a treat-to-target strategy. <i>Scandinavian Journal of Rheumatology</i> , 2018 , 47, 351-359	1.9	6
73	Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians: Differences Across Countries in the METEOR Database. <i>Journal of Clinical Rheumatology</i> , 2015 , 21, 349-54	1.1	6

72	Pharmacogenetics/pharmacogenomics and antirheumatic drugs in rheumatology. <i>Pharmacogenomics</i> , 2004 , 5, 1107-16	2.6	6
71	Correspondence on 'Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis'. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	6
70	Pulmonary intravascular coagulopathy in COVID-19 pneumonia. <i>Lancet Rheumatology, The</i> , 2020 , 2, e458-4.2	4.2	6
69	EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	6
68	Microvascular heart involvement in systemic autoimmune diseases: The purinergic pathway and therapeutic insights from the biology of the diseases. <i>Autoimmunity Reviews</i> , 2019 , 18, 317-324	13.6	5
67	ZAP-70+ B cell subset influences response to B cell depletion therapy and early repopulation in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2012 , 39, 2276-85	4.1	5
66	Pharmacogenetic of antirheumatic treatments: clinical implications. <i>Pharmacogenomics Journal</i> , 2007 , 7, 2-9	3.5	5
65	Cyclosporine A pharmacokinetics in rheumatoid arthritis patients after 6 months of methotrexate therapy. <i>Pharmacological Research</i> , 1999 , 40, 483-6	10.2	5
64	The Chronic Arthritis Systemic Index: a nomogram to assess the activity and severity of chronic arthritis. <i>Arthritis and Rheumatism</i> , 1993 , 36, 1180-1		5
63	Cyclosporin A increases somatomedin C insulin-like growth factor I levels in chronic rheumatic diseases. <i>Journal of Rheumatology</i> , 1995 , 22, 1060-4	4.1	5
62	Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a analysis of a phase III trial. <i>RMD Open</i> , 2019 , 5, e000934	5.9	5
61	Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	5
60	Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA. <i>Joint Bone Spine</i> , 2021 , 88, 105062	2.9	5
59	Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 660-665	2.2	5
58	Selective Inhibitors of T Cell Receptor Recognition of Antigen-MHC Complexes for Rheumatoid Arthritis. <i>ACS Medicinal Chemistry Letters</i> , 2019 , 10, 644-649	4.3	4
57	Thymosin α 1 and α 2 in Sjögren's syndrome: saliva proteomics and minor salivary glands expression. <i>Arthritis Research and Therapy</i> , 2016 , 18, 229	5.7	4
56	Tofacitinib for rheumatoid arthritis. <i>Lancet, The</i> , 2013 , 381, 1812	4.0	4
55	Association between the response to B cell depletion therapy and the allele*2 of the HS1,2A enhancer in seropositive rheumatoid arthritis patients. <i>Reumatismo</i> , 2012 , 64, 368-73	1.1	4

54	Immunosuppressive Therapy (Methotrexate or Cyclophosphamide) in Combination with Corticosteroids in the Treatment of Giant Cell Arteritis: Comparison with Corticosteroids Alone. <i>Journal of the American Geriatrics Society</i> , 2016 , 64, 672-374	5.6	4
53	Comprehensive review on intravertebral intraspinal, intrajoint, and intradiscal vacuum phenomenon: From anatomy and physiology to pathology. <i>Modern Rheumatology</i> , 2021 , 31, 303-311	3.3	4
52	CTLA-4 Ig as an effective treatment in a patient with type I diabetes mellitus and seropositive rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 315-7	2.2	4
51	Do we need to apply a T2T strategy even in ACPA-negative early rheumatoid arthritis? YES. <i>RMD Open</i> , 2016 , 2, e000263	5.9	3
50	Gut microbiota analysis in systemic sclerosis according to disease characteristics and nutritional status. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 125, 73-84	2.2	3
49	Should rheumatoid factor (RF) (and antinuclear antibodies (ANA)) become routinary screening test for morbidities in the general population?: From the concept of "benign autoimmunity "to the concept of" autoimmunity as a red flag in preventive medicine"?. <i>Autoimmunity Reviews</i> , 2018 , 17, 636-638	13.6	2
48	Should we consider tumor necrosis factor as the only target in spondyloarthritides?. <i>Journal of rheumatology Supplement, The</i> , 2012 , 89, 94-6		2
47	OP0178 The Body Mass Index: A Determinant of Remission in Early Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A113.2-A113	2.4	2
46	Atlantoepistropheic magnetic resonance imaging involvement in early rheumatoid arthritis: an aggressive tight control therapy not fully arresting the disease. <i>Arthritis Care and Research</i> , 2011 , 63, 1629-33	4.7	2
45	Analysis of response to infliximab in ankylosing spondylitis according to the axial and/or peripheral involvement: autoantibodies and drop outs are more frequent in the peripheral subset. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 427-8	2.4	2
44	Immune-guided therapy of COVID-19.. <i>Cancer Immunology Research</i> , 2022 ,	12.5	2
43	Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies. <i>Frontiers in Medicine</i> , 2020 , 7, 553075	4.9	2
42	More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	2
41	Is Citrullination Required for the Presence of Restricted Clonotypes Reacting With Type II Collagen? Comment on the Article by Chemin et al. <i>Arthritis and Rheumatology</i> , 2016 , 68, 2052-3	9.5	2
40	Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry" by Sparks. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	2
39	Inclusion of Synovial Tissue-Derived Characteristics in a Nomogram for the Prediction of Treatment Response in Treatment-Naive Rheumatoid Arthritis Patients. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1601-1613	9.5	2
38	() as a Potential Driver of Molecular Mimicry and Inflammation in Rheumatoid Arthritis. <i>Frontiers in Medicine</i> , 2021 , 8, 671018	4.9	2
37	Comment on "Tumor necrosis factor- α antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study". <i>Clinical Rheumatology</i> , 2016 , 35, 839-40	3.9	1

36	Comment on: Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2020 , 59, 1782-1783	3.9	1
35	Outcomes and Findings of the International Rheumatoid Arthritis (RA) BIODAM Cohort for Validation of Soluble Biomarkers in RA. <i>Journal of Rheumatology</i> , 2020 , 47, 796-808	4.1	1
34	Morbidity and Mortality From COVID-19 Are Not Increased Among Children or Patients With Autoimmune Rheumatic Disease-Possible Immunologic Rationale: Comment on the Article by Henderson et al. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1772-1774	9.5	1
33	Response to letter by Aramugakani et al. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, e21	2.4	1
32	THU0525 Metaflammation, PEDF and Chemerin: Potential Systemic Factors Which Link Obesity to Response to Therapy in Early Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 364.3-365	2.4	1
31	THU0532 Distribution of Body Mass Index and Metabolic Syndrome in Patients with Inflammatory Autoimmune Diseases from a Single Italian Centre. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A344.1-A344	3.4	1
30	AB0465 Etanercept therapy in rheumatoid arthritis patients with moderate or severe disease activity. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 664.5-664	2.4	1
29	Biologics use in sle in 23 centers [Data from the international registry for biologics in SLE. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, A9.1-A9	2.4	1
28	Infections, rheumatism and autoimmunity. <i>Future Rheumatology</i> , 2008 , 3, 223-225		1
27	B cell depletion and a T cell-targeted therapy allows to control the sudden onset of diabetes and lupus, without steroids. <i>Acta Diabetologica</i> , 2008 , 45, 195-6	3.9	1
26	The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts. <i>Autoimmunity Reviews</i> , 2018 , 17, 1251-1258	13.6	1
25	Unmet Needs in the Treatment of RA in the Era of Jak-i: IDRA (Italian Delphi Rheumatoid Arthritis) Consensus. <i>BioMed Research International</i> , 2018 , 2018, 3878953	3	1
24	Measuring the T-cell down-regulation of TCR-zeta, ZAP-70 and CD28 in arthritis patients: An old tool for new biomarkers. <i>European Journal of Immunology</i> , 2019 , 49, 2195-2203	6.1	0
23	Lupus anticoagulant and ischemic myocardial microangiopathy in rheumatoid arthritis. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006 , 3, 339-43; quiz following 343		0
22	Factors Predicting Early Failure of Etanercept in Rheumatoid Arthritis: An Analysis From the Gruppo Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis) Registry. <i>Archives of Rheumatology</i> , 2020 , 35, 163-169	0.9	0
21	Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry. <i>Clinical Rheumatology</i> , 2021 , 40, 4039-4047	3.9	0
20	RAASI, NSAIDs, antidiabetics, and anticoagulants: More data needed to be labeled as harmful or neutral in SARS-CoV-2 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	0
19	Systemic Bone Density at Disease Onset Is Associated With Joint Erosion Progression in Early Naive to Treatment Rheumatoid Arthritis: A Prospective 12-Month Follow-Up Open-Label Study. <i>Frontiers in Medicine</i> , 2021 , 8, 613889	4.9	0

18	Infectious agents breaking the immunological tolerance: The holy grail in rheumatoid arthritis (RA) reconsidered.. <i>Autoimmunity Reviews</i> , 2022 , 103102	13.6	0
17	OP0274 Cryoglobulinemic Vasculitis and Primary sjögren's Syndrome are Independent Risk Factors for Lymphoma in a Large Worldwide Population of Patients with Positive Serum Cryoglobulins. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 175.3-176	2.4	
16	FRI0096 Haq baseline values in an international registry of ra patients during the era of biologic therapies: the 2013 meteor database.. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A402.1-A402	2.4	
15	AB0770 Rheuma-card: involvement of the patient through a secure systems access into the treat to target strategy in rheumatology.. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A1025.1-A1025	2.4	
14	SAT0199 An estimate of the proportion of patients with sle receiving off-label treatment with rituximab in european countries. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 539.1-539	2.4	
13	SAT0175 Results of the Classification Criteria for Cryoglobulinemic Vasculitis Validation Study. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A640.2-A641	2.4	
12	B cell receptor repertoire analysis in clinically involved and uninvolved skin of systemic sclerosis patients treated with CD20 depletion therapy: baseline and follow-up. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, A62-A63	2.4	
11	Chapter 8 Gastrointestinal Involvement in Systemic Vasculitis. <i>Handbook of Systemic Autoimmune Diseases</i> , 2008 , 8, 83-298	0.3	
10	Pharmacogenetics, Target Molecules, and Biological Anti-Rheumatic Drugs in Autoimmune/Chronic Inflammatory Rheumatic Diseases. <i>Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics</i> , 2006 , 4, 105-111		
9	Indomethacin-related serum sickness-like illness with IgM lambda cryoparaprotein?. <i>Acta Haematologica</i> , 1985 , 73, 45-6	2.7	
8	FRI0574 RENAL TISSUE EPIGENETIC BIOMARKERS CHARACTERIZATION IN PATIENTS WITH LUPUS NEPHRITIS AS PARAMETERS OF DISEASE ACTIVITY, REMISSION AND FLARE. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 889.2-890	2.4	
7	SAT0224 ANTIPHOSPHOLIPID ANTIBODIES AND VASCULAR RENAL LESIONS AS PROGNOSTIC FACTORS IN LUPUS NEPHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1055.3-1055	2.4	
6	THU0287 EVALUATION OF PREDICTIVE FACTORS OF WORSE PROGNOSIS IN LUPUS NEPHRITIS: FOCUS ON NEW PATHOGENETIC PATHWAYS. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 370.3-370	2.4	
5	AB0102 SPECIALIZED PRO-RESOLVING MEDIATOR RECEPTORS AS INFLAMMATORY RESOLUTION BIOMARKERS IN RHEUMATOID ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1350.3-1350	2.4	
4	Rheumatologic Symptoms in Patients with Mixed Cryoglobulinemia 2012 , 185-190		
3	Weight Loss, The Obesity Paradox in Rheumatoid Arthritis: Is It a Paradox? Comment on the Article by Baker et al. <i>Arthritis and Rheumatology</i> , 2016 , 68, 553	9.5	
2	L'indice de masse corporelle n'a pas d'impact sur la réponse à l'abatacept sous-cutané ou intraveineux chez les patients souffrant de polyarthrite rhumatoïde. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2016 , 83, A167-A168	0.1	
1	Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: results of an Italian observational study. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 919-928	2.2	

